Advanced Prostate Cancer Videos

Lutetium-177 PSMA-617 Therapy Across the Prostate Cancer Spectrum: Mechanism, Formulation, and Future Directions - Phillip Koo

Implementation of the PC360 Algorithm to Manage Cardiovascular and Bone Health Risks on ADT - Jason Hafron

Radioligand Therapy and Patient Selection Criteria for Lu-PSMA-617 - Phillip Koo

Large-Scale Data Linkage Reveals Genomic Differences in De Novo Metastatic Prostate Cancer - Shalini Moningi

Bone-Modifying Agents in Prostate Cancer: Distinguishing Osteoporosis from Skeletal-Related Events - Matthew Smith

Nutritional Counseling for Prostate Cancer Patients Receiving Systemic Therapy - Maria De Santis

Examining the Role of Metastasis-Directed Therapy Alone Versus Combined Approaches in Oligometastatic Prostate Cancer - Kosj Yamoah

Debating Prostate Radiotherapy for Metastatic Hormone-Sensitive Prostate Cancer - Tyler Seibert

Real-World Data Explores Post-177Lu-PSMA-617 Therapies in Advanced Prostate Cancer - Xiao Wei

ProTACT Trial Investigates Next-Generation PSMA-Targeted Alpha Therapy for mCRPC - Aaron Hansen

Phase I PAnTHA Study Evaluates PSMA-Targeted Actinium-225 in mCRPC Patients - Fred Saad

Predicting Non-Cancer Mortality Risk in mHSPC Following Doublet Therapy Using STAMPEDE Data - Noel Clarke

PSMAddition "Presentation" - Oliver Sartor

SPECT Versus PET: Optimizing Response Biomarkers "Presentation" - Lisa Bodei

Patient Selection for Intermittent Therapy: The Role of PSA Nadir and Disease Volume - Maha Hussain

Working Group 4 Introduces Updated Terminology for Advanced Prostate Cancer - Andrew Armstrong

CIPHER Trial Investigates Carboplatin in mCRPC Patients with HRR Mutations - Atul Batra

PCWG4 Amends Terminology and Biomarker Standards for Advanced Prostate Cancer - Andrew Armstrong

PEACE-3 Trial Evaluates Radium-223 Plus Enzalutamide in Bone-Metastatic mCRPC - Enrique Gallardo Diaz

BRCAAway Trial Investigates Combination Versus Sequencing of ARPI and PARP Inhibitor in mCRPC - Maha Hussain

Phase 2 TheraPb Trial Evaluates a Novel Induction and Maintenance Regimen of 212Pb-ADVC001 Across Three Metastatic Prostate Cancer Indications - Anna Karmann

EZH2 Inhibition Combined with ARPI Evaluated in Patients with Castration-Resistant Prostate Cancer - Nobuaki Matsubara

Obrixtamib Monotherapy Assessed in DLL3-Selected Extrapulmonary Neuroendocrine Tumors - Nil Navarro-Gorro

Cluster-Randomized Trial Targets Barriers to Mainstream Germline Testing for Veterans - Daniel Kwon

Real‑World Use of Radium‑223 in Veterans with Metastatic CRPC: A National Analysis - Martin Schoen

mHSPC Treatment Selection: ARPI Backbone, Biomarkers, and Docetaxel – Christopher Sweeney

Real-World Analysis of Lutetium-177 in mCRPC by Taxane Treatment Sequence - Micah Ostrowski

Large-Scale Analysis Examines Inherited DNA Damage Repair Genes in Advanced Prostate Cancer - Sofie Tolmeijer

OPTIMAS Trial: Testing Intermittent Therapy in Metastatic Hormone-Sensitive Prostate Cancer - Umang Swami

Masofaniten Combined with Enzalutamide Investigated in Metastatic Hormone-Sensitive Prostate Cancer - Albert Jang

POSEIDON Meta-Analysis Re-examines the Role of ADT with Salvage Radiation for Prostate Cancer - Amar Kishan

Selective PARP1 Inhibition Combined with ARPIs Under Investigation in the PETRANHA in mHSPC - Arun Azad

Longitudinal Analysis of Patient-Reported Outcomes in the PSMAddition Trial - Michael Morris

ECLIPSE Trial Explores Dosimetry for PSMA-Targeted Therapy in mCRPC - Frankis Almaguel & Jason Hafron

Practical Approaches to Genetic Testing in Metastatic Hormone-Sensitive Prostate Cancer - Emmanuel Antonarakis

OMAHA-003 Trial Explores CYP11A1 Inhibition in Metastatic Castration-Resistant Prostate Cancer - Evan Yu

MEVPRO-3 Trial: Testing EZH2 Inhibition in First-Line Metastatic Hormone-Sensitive Prostate Cancer - Neeraj Agarwal

A Multidisciplinary Approach to Supporting Patients with Metastatic Hormone-Sensitive Disease - Jack Andrews

ASPIRE Trial: Evaluating Docetaxel's Role in Metastatic Hormone-Sensitive Prostate Cancer - Deepak Kilari & Rana McKay

The PLUDO Study: Comparing First-Line Lutetium vs Docetaxel in Chemo-Naive Metastatic Prostate Cancer - Kim Chi

Prognostic Tool Evaluated For Early Treatment Decisions for Metastatic Hormone-Sensitive Prostate Cancer - Soumyajit Roy

Biomarker Data from Phase II PT-112 Trial in Heavily Pretreated mCRPC - Alan Bryce

PTEN Loss and the Future of Precision Treatment in mHSPC - Karim Fizazi & Noel Clarke

Phase 1 Study Evaluates Bone Metastasis Resolution with SYNC-T Therapy SV-102 - Gerald Andriole

Radioligand Therapy Induced DNA Damage Response Kinetics and Biomarker Strategies - Katharina Lückerath & Ken Herrmann

Phase 1 Dosing Strategy and Translational Findings for Investigational Therapy Pasritamig - Karen Autio

Association of PSA Trajectories with Survival in mHSPC from ARASENS and ARANOTE Trials - Christopher Wallis

LUNAR Trial: Neoadjuvant Lutetium-PSMA Plus SBRT Evaluated in Oligometastatic Prostate Cancer - Amar Kishan & Jeremie Calais

Clinical and Molecular Criteria for Aggressive Variant Prostate Cancer - Ana Aparicio

Investigational All-in-One CAR T-Cell Platform for Prostate Cancer - Nour Shobaki

Genomic Testing and the Evolving Role of PARP Inhibitors in Prostate Cancer - Tanya Dorff

Implementing Systemic Biomarker Testing for Metastatic Prostate Cancer Patients - Pedro Barata

Investigational Therapies Target STEAP1 and DLL3 in Advanced Prostate Cancer - Rahul Aggarwal

GTB-5550: A Tri-specific NK Cell Engager Designed to Target B7-H3 - Nicholas Zorko

Multidisciplinary Care, Early Detection, and Ongoing Prostate Cancer Challenges - Maha Hussain

PRESTO Trial Final Results for High-Risk Biochemically Recurrent Prostate Cancer - Rahul Aggarwal

Systematic Review Evaluates Radiologic Progression-Free Survival as a Surrogate for Overall Survival in mHSPC - Neal Shore & Alicia Morgans

Moving Beyond DNA: The Role of Early, Multi-Modal Genomic Testing in Prostate Cancer Management - Colin Pritchard

Investigational RIPTAC™ Therapy (HLD-0915) in Phase I mCRPC Study – Andrew Hahn

Exploring STEAP1 in Prostate Cancer: From CRISPR Screens to a Neoadjuvant Bispecific Trial - Carissa Chu

Precision Medicine in Advanced Prostate Cancer: Key Advances and What’s Next - Emmanuel Antonarakis

Phase 1B Trial Combines Xaluritamig with Hormone Therapy for Metastatic Prostate Cancer - Nicholas Zorko

Optimizing Advanced Prostate Cancer Care: Balancing Intensification and Overtreatment - Gerhardt Attard

Targeting NSD2 to Reverse Treatment Resistance in Advanced Prostate Cancer - Jia Li

Targeting SPP1+ Macrophages and the Adenosine Pathway to Boost Prostate Cancer Immunotherapy - Lawrence Fong

ARTISAN Trial: Evaluating Lead-212 PSMA Therapy for Advanced Prostate Cancer - Oliver Sartor

International Analysis of Anti-PD-1/PD-L1 Efficacy and Biomarker Selection in Mismatch Repair-Deficient mCRPC - Niven Mehra

Study on Metastatic Hormone-Sensitive Prostate Cancer Survival Trends - Neeraj Agarwal

A SEER Database Analysis of Real-World Survival Trends in Metastatic Prostate Cancer - Pedro Barata

Analysis of Patient-Reported Quality of Life from the AMPLITUDE Trial - Eleni Efstathiou

PARP Inhibitors in Prostate Cancer: A Decade of Development and the Combination vs Monotherapy Debate for HRR-Mutated Disease - Neeraj Agarwal

Following the AMPLITUDE Trial: Addressing Challenges and Implementing Biomarker Testing for mHSPC - Pedro Barata

ctDNA as an Early Response Signal in RLT and mCRPC Care - Alexander Wyatt

Pasritamig Bispecific Antibody in Metastatic Castration-Resistant Prostate Cancer - Mark Stein

Pre-ESMO 2025 Highlights - Rashid Sayyid & Zachary Klaassen

NRG-GU006 Trial for Post-Prostatectomy Radiation Therapy - Daniel Spratt

Phase 1 Trial of an Actinium-Labeled KLK2-Targeting Antibody for mCRPC - Michael Morris

Phase 2 EXTEND Trial of Metastasis-Directed Therapy with Continuous Hormone Therapy - Alexander Sherry & Bilal Siddiqui

Validating the APUC-6 Signature in mHSPC from the ECOG-ACRIN E3805 CHAARTED Trial - Xiaolei Shi

Phase I Study of SYNC-T Combination Therapy for Metastatic Castration-Resistant Prostate Cancer - Jason Hafron

Elevating the Patient Voice: Understanding Treatment Preferences in Patients with Advanced Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen

PSMA PET and Radionuclide Therapy in Colombia - Carlos Granados

Phase II LUNAR Trial Results: Adding Lutetium PSMA to SBRT for Oligorecurrent Prostate Cancer - Amar Kishan

Prostate Cancer Treatment Intensification: From Clinical Evidence to Real-World Application - Julian Chavarriaga & Luis Salgado

Defining High-Risk Biochemical Recurrence and its Clinical Implications - Ricardo Rendon

Metastasis-Directed Therapy for Low-Volume mHSPC - Luis Salgado

AI's Role in Prostate Cancer Diagnosis, Imaging, and Pathology - Matthew Cooperberg

Biomarker Applications in Localized and Advanced Prostate Cancer - Julian Chavarriaga

Considerations for Patient Selection and Imaging in PSMA-Targeted Therapy - Tanya Dorff & Julie Graff

Managing mHSPC with ADT and ARPI Therapy - Brian Chapin & David Morris

Diagnostic and Staging Approaches for Localized Neuroendocrine Prostate Cancer - Joshua Lang & Rana McKay

Treatment Sequencing and PARP Inhibitors in Advanced Prostate Cancer - Tanya Dorff

Development of a Prognostic Model Combining Clinical and Genetic Features in mCRPC - Andrew Armstrong

Overall Survival Results from the TALAPRO-2 Trial in mCRPC Patients - Neeraj Agarwal

Discussion on the Use of Bone Modifying Agents in Metastatic Prostate Cancer - Tian Zhang and Evan Yu

Discussion on Patient Selection for Radioligand Therapy in Prostate Cancer - Oliver Sartor and Daniel Petrylak

Discussion on Treatment Sequencing for mCRPC After Progression on ADT, ARPI, and Docetaxel - Phillip Kuo & Oliver Sartor

Considerations for Patient Selection in PSMA Radioligand Therapy - Scott Tagawa & Alan Bryce

Gene-Specific Analysis of PARP Inhibitor Response in Prostate Cancer - Pedro Barata

Association Between SPOP Gene Mutations and Response to Androgen Therapy - Neeraj Agarwal & Daniel Petrylak

Examining the Role of Tumor Suppressor Gene Loss and Chemotherapy Intensification in Prostate Cancer - Matthew Smith

Discussion on Biomarker Selection for Immunotherapy in Prostate Cancer - Michael Carducci & Tian Zhang

Phase III PSMAfore Trial: Final Survival and Safety Data in mCRPC, Journal Club - Rashid Sayyid & Zachary Klaassen

ctDNA Biomarkers in TheraP Trial: Cabazitaxel vs Lutetium-PSMA Comparison - Alexander Wyatt

Study Examines Racial Disparities in PSMA-PET Imaging Utilization for Metastatic Prostate Cancer - Eunice Hankinson

Advances in Targeting Cell Surface Proteins in Prostate Cancer - Andrew Hahn

COMRADE Trial: Radium-223 Plus Olaparib in Bone-Predominant mCRPC - Rana McKay

Pasritamig Safety and Efficacy Data from Metastatic CRPC Phase I Study - Capucine Baldini

EVOLUTION Trial: Ipilimumab/Nivolumab Plus Lutetium-PSMA Improves mCRPC Outcomes - Shahneen Sandhu

Darolutamide in AR-Altered mCRPC: Biomarker-Selected Phase II Trial Results - Michael Ong

Consensus Recommendations for PSMA PET Imaging and Treatment Strategies in Biochemical Recurrence - Mary-Ellen Taplin

Consensus Recommendations for PARP Inhibitor Use in Metastatic Prostate Cancer - Michael Carducci

Consensus Recommendations for ARPI Sequencing and Radioligand Therapy in mCRPC - Michael Morris

Consensus Recommendations for PSMA PET Imaging in Metastatic Prostate Cancer - Tanya Dorff

Xaluritamig vs. Standard Care: A Phase 3 Trial for ARPI/Taxane-Refractory mCRPC - William Kevin Kelly

C3NIRA Trial Findings in High-Risk Prostate Cancer Population - Ana Aparicio

Radium-223 + Enzalutamide in mCRPC: Revisiting PEACE-3 Trial Data - Kristine Peregrino Lacuna

Differential Treatment Responses Across HRR Gene Alterations in Prostate Cancer - Stefanie Zschäbitz

PSA Thresholds in mHSPC: What VA Data Reveals About Optimal Targets - Stephen Freedland

Dissecting Tumor Mutational Burden and Microsatellite Instability in mCRPC: Differential Responses to Immune Checkpoint Inhibitors - Nicolas Sayegh

Darolutamide + ADT Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer - Hanan Goldberg

Personalizing Lutetium-177 Dosing: The FLEX-MRT Trial Approach - Adrien Holzgreve

HRR Gene Defects Predict Rapid Progression in mHSPC Patients - Elena Castro & David Olmos

Lutetium Lu 177 Timing Study: Early vs. Late Post-Chemo PSA Response - Eman Ahmed & Jack Andrews

Circulating Tumor Cell Phenotypes and Genomic Mutations Stratify mCRPC Risk - Marina Sharifi

Personalizing mHSPC Treatment: When to Add Chemotherapy to Darolutamide and ADT - Kristine Peregrino Lacuna

SUVmean on PSMA PET Predicts Lutetium-PSMA Therapy Success in mCRPC - Koichiro Kimura

PTEN Inactivity Signature Predicts Docetaxel Benefit in Advanced Prostate Cancer - Emily Grist

Fracture Incidence Patterns Among Advanced Prostate Cancer Patients Receiving Androgen Receptor Pathway Inhibitors - Grace Lu-Yao

Racial Disparities in Prostate Cancer Genomics and PARPi Treatment Outcomes - Sharon Choi & Qian Qin

Pluvicto™ Expands to Pre-Chemotherapy Space for PSMA-Positive Prostate Cancer - Steven Finkelstein

DLL3-Targeted Theranostics for Neuroendocrine Prostate Cancer - Salomon Tendler

Uncovering Blood Mutation Risks in Advanced Prostate Cancer Therapies - Asli Munzur

ENZA-p Trial: PSMA PET Guides Treatment Choice for Metastatic Prostate Cancer - Louise Emmett

Real-World Prostate Cancer Treatment Patterns in Colombia - Ray Manneh Kopp

Androgen Receptor Mutations in Prostate Cancer: Impact on Enzalutamide Response - Matthew Siskin

Real-World VA Study Explores Use of ARPIs in Metastatic Hormone-Sensitive Prostate Cancer - Martin Schoen

TRIPLE-SWITCH Trial Tests Docetaxel Addition for mHSPC Patients with Suboptimal PSA Response - Alexandra Sokolova

Tazemetostat + Talazoparib for Metastatic Castration-Resistant Prostate Cancer - Atish Choudhury

PSMA PET in Biochemical Recurrence: When to Treat vs When to Wait - Ravi Madan

Talazoparib-Enzalutamide Combintation and Quality of Life in mCRPC Patients - Nobuaki Matsubara

Emerging Prognostic Value of Molecular Imaging in Prostate Oncology - Wolfgang Fendler

Exploring IGF-1 Pathway Biomarkers and Outcomes in Metastatic Hormone-Sensitive Prostate Cancer - Lisa Horvath

One-Button PSMA PET Quantification Predicts Survival in Metastatic Prostate Cancer - Louise Emmett

Lutetium-177 Outperforms Cabazitaxel in mCRPC: Real-World Flatiron Database Analysis - Zeynep Irem Ozay

PEACE-3 Trial: Enzalutamide Plus Radium-223 Improves Survival in mCRPC, Journal Club - Rashid Sayyid & Zachary Klaassen

Terbium-161 vs Lutetium-177: Comparing Next-Gen Radioligands for Prostate Cancer - Michael Hofman

EZH2 Inhibition in Prostate Cancer: MEVPRO-1 Phase III Trial Update - Neeraj Agarwal

Racial Disparities in mCRPC Treatment: Equal Outcomes with Equal Access to Care - Stephen Freedland

PSMA DC Trial: Lutetium + SBRT to Delay ADT in Oligometastatic Prostate Cancer - Oliver Sartor

B7-H3 Targeting ADC in Castrate-Resistant Prostate Cancer Trial - Andrew Parsonson

PSMA PET Scans Predict Enzalutamide Efficacy in Metastatic Prostate Cancer - Louise Emmett

AMPLITUDE Trial: Niraparib Delays Progression in HRR-Mutant Prostate Cancer - Gerhardt Attard

Subgroup Analysis Confirms Darolutamide Efficacy in Black Prostate Cancer Patients - Quoc-Dien Trinh

EMBARK Subgroup Analysis: Enzalutamide Monotherapy Effective Regardless of Prior Definitive Therapy - Stephen Freedland

TRIPLE-SWITCH Trial: Intensifying Treatment for Suboptimal PSA Response in mHSPC - Michael Ong, Alexandra Sokolova & Tanya Dorff

Real-World Data Explores Benefits of Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Benjamin Maughan

Genomic and Clinical Profiles of Rapidly Progressing mCRPC Patients - Maha Hussain

Phase I Trial Combines ONC-392 with Lutetium-177 for Prostate Cancer - David Wise

Actinium-PSMA J591 After Prior Lutetium Therapy in Metastatic Prostate Cancer - Scott Tagawa

EMBARK Analysis: Testosterone Recovery Post-ADT in High-Risk Prostate Cancer Patients - Stephen Freedland

Apalutamide vs Enzalutamide: Racial Disparities in mCSPC Treatment Outcomes - Benjamin Lowentritt

HSPC to mCRPC: Management Current Approaches and Future Developments - Michael Cookson & Jason Efstathiou

TRITON3 Subgroup Analysis: Rucaparib Benefits BRCA+ Patients with Liver Mets - David Morris

Combining Alpha and Beta Emitters in PSMA-Targeted Prostate Cancer Therapy - Scott Tagawa

PSMA-PET Improves Metastasis-Free Survival in Salvage Radiotherapy for Prostate Cancer - Antony Pellegrino

PRECISION Data Platform Reveals mCRPC Treatment Outcomes in Urology Practices - Neal Shore

ARANOTE Study Shows Benefits of Deep PSA Response with Darolutamide - Neal Shore

Optimizing Multidisciplinary Care for Metastatic Hormone-Sensitive Prostate Cancer - Zachary Klaassen

BMS-986365: Targeting AR Degradation and Antagonism in Metastatic Prostate Cancer - Manish Patel

EMBARK Trial: Treatment Options for High-Risk Biochemical Recurrence - Neal Shore

CDK12 Loss Drives Prostate Cancer Progression and Creates Therapeutic Vulnerability - Jean Tien

PSMA Positive Extracellular Vesicles as Biomarkers in Oligometastatic Prostate Cancer - Jack Andrews

ONECUT2 Crystal Structure Reveals Potential for Targeted Prostate Cancer Therapy - Brad Gallent

High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes - Marina Sharifi

Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer in the US - Umang Swami

Improving PSA Doubling Time Calculation for High Risk Biochemical Recurrence - Alicia Morgans

Prognostic Value of ctDNA Fraction in Metastatic Castration-Resistant Prostate Cancer - Alessio Crippa

PARASEC Study Reveals Real-World Treatment Patterns After Darolutamide in ARAMIS Trial - Javier Puente

PSA Nadir Predicts Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Patients - Hannah McManus

Real-World Treatment Delays Between Lutetium-177 and Cabazitaxel in Advanced Prostate Cancer - Yeonjung Jo & Umang Swami

SPP1 Macrophages and Immunotherapy Resistance in Advanced Prostate Cancer - Aram Lyu

PSA Responses with Darolutamide Plus ADT in the ARANOTE Trial - Fred Saad

ARASENS Trial Analysis Investigates Impact of Initial PSA Values on Treatment Response in mHSPC - Alicia Morgans

Bone-Protective Agents and Survival Benefits in PEACE-3 Trial Subgroup Analysis - Fred Saad

Comparing EMBARK vs EAU High-Risk Biochemical Recurrence Criteria in Prostate Cancer - Ugo Falagario

TRITON3 Final Overall Survival Results for Rucaparib in BRCA-Mutated Prostate Cancer - Alan Bryce

LIBERTAS Clinical Trial Explores Treatment Optimization in mHSPC - Arun Azad

Investigating PARP Expression as Biomarker for Targeted Therapy in Prostate Cancer - Emmanuel Antonarakis

Examining Post-Prostatectomy Metastasis Patterns in Hormone-Sensitive Prostate Cancer - Nicolas Sayegh

Comparing ARPI Options Across Disease Volume and Metastatic Timing in mHSPC - Syed Arsalan Ahmed Naqvi & Irbaz Riaz

PERSIAN Trial Explores SBRT Benefits in Oligometastatic Hormone-Sensitive Prostate Cancer - Giulio Francolini

Talazoparib and Enzalutamide in Unselected mCRPC Patients - Neeraj Agarwal

Real-World Data on Treatment Patterns After PSMA-Targeted Therapy in mCRPC - Oliver Sartor

Targeting Lineage Plasticity in Prostate Cancer with EZH2 Inhibitor Mevrometostat - Michael Schweizer

Systematic Review of Real-World Outcomes of Radium-223 in mCRPC Treatment - Rana McKay

Phase II ENZA-p Trial Explores Effect of Lutetium PSMA With Enzalutamide - Louise Emmett

Cardiovascular Management in Advanced Prostate Cancer - Zeynep Irem Ozay

EMBARK Trial Subanalysis for High-Risk Biochemical Recurrent Prostate Cancer - Stephen Freedland

Estrogen Patches Combined with AR Pathway Inhibitors Show Promise in Prostate Cancer Management - Nicholas James

Tumor Suppressor Gene Status Refines Prognosis and Treatment Selection in Metastatic Prostate Cancer - Martino Pedrani

Comparing Industry-Sponsored and Investigator-Initiated Trials in Genitourinary Oncology - Srikala Sridhar

IMPLEMENT Study Reveals Barriers to Treatment Intensification in Metastatic Prostate Cancer - Stacy Loeb

Underutilization of Genomic Testing in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata

Lutetium PSMA Therapy in mCRPC: Real-World Evidence from PRECISION Data Platform - Oliver Sartor

Metastasis-Directed Therapy Improves Outcomes in Oligometastatic Prostate Cancer in WOLVERINE Study - Chad Tang

177-Lutetium-PSMA vs Cabazitaxel: A Real-World mCRPC Study - Mike Wenzel

ACCEL Trial Tests Actinium-225-PSMA-62 in Prostate Cancer - Ramy Saleh

Real-World Trends in Bone Health Agent Use for Metastatic Prostate Cancer - Umang Swami

REDUSE Trial: Comparing Denosumab Dosing Intervals in mCRPC - Arnoud Templeton

Patient-Level Data Confirms ARPI Value in mHSPC Treatment in Meta-Analysis - David Fisher

Darolutamide Monotherapy in Prostate Cancer: A Phase II Trial Overview - Xin Gao

Exploring Actinium-225 in PSMA-Targeted Therapy for Prostate Cancer - Michael Morris

Real-World Treatment Patterns in Advanced Prostate Cancer from PRECISION Data Platform - Oliver Sartor

ARASTEP Trial Tests Darolutamide and ADT in High-Risk Biochemically Recurrent Prostate Cancer - Alicia Morgans

Talazoparib Improves Survival in HRR-Mutated mCRPC Patients in TALAPRO-2 Trial - Karim Fizazi

ARANOTE Trial Explores Darolutamide’s Role in High and Low-Volume Metastatic Prostate Cancer - Fred Saad

Lineage-Specific EZH2 Activity in Advanced Prostate Cancer Subtypes - Varadha Balaji Venkadakrishnan

Intratumoral Heterogeneity Drives Therapy Resistance in Metastatic Prostate Cancer - Laura Sena

Canonical Androgen Response Elements in Prostate Cancer Growth Suppression - Christopher Barbieri

ADT Remodels the Tumor Microenvironment from Immunologically Cold to Hot - Matthew Dallos

ASCL1 and FOXA2 in Neuroendocrine Prostate Cancer - Shaghayegh Nouruzi

CDK12 Mutation Types and PARP Treatment Effectiveness - Jonathan Chou

PARP Inhibitor Resistance Mechanisms in Prostate Cancer - Johann De Bono

Universal Germline Genetic Testing for Prostate Cancer Patients - Neal Shore & Sarah Young

Physician Decision Making & Combination Therapies in Metastatic Prostate Cancer - Neeraj Agarwal

AR EcDNA Discovery in Advanced Prostate Cancer Study - George Zhao

Machine Learning Stemness Signature for Prostate Cancer - Agustina Sabater & Geraldine Gueron

Opevesostat Trial in mCRPC: Targeting Androgen Biosynthesis Upstream for Improved Outcomes - Christian Gratzke

ProstACT GLOBAL Trial: Combining PSMA-Targeted Therapy with ARPIs and Docetaxel - Oliver Sartor

Urinary Incontinence in Gay and Bisexual Prostate Cancer Survivors - Kristine Talley

Classifying FOXA1 Alterations: Implications for Prostate Cancer Prognosis and Treatment - Emmanuel Antonarakis & Justin Hwang

Combining EZH2 and AR Targeting in Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal

AR Enhancer Amplification and SSTR1 Downregulation in mCRPC - Xiaolin Zhu

Effectiveness of PSMA-Lutetium for Prostate Cancer Liver Metastases - Daniel Childs

MYC’s Role in Prostate Cancer Immune Suppression and Progression - Mindy Kim Graham

Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis - Ken Herrmann

The Proteogenomics of Prostate Cancer Radioresistance - Roni Haas

Study Reveals How Prostate Cancer Alters Bone Structure, Increasing Fracture Risk - Felipe Eltit Guersetti

Online Platform Maps Theranostic Trials Worldwide for Patients and Physicians - Luke Nordquist

Polyaneuploid Cancer Cells Drive Metastasis and Resist Treatments in Prostate Cancer - Sarah Amend

VA Study Examines Use of Combination Therapies for mHSPC and Outcomes in Patients - Martin Schoen & Bruce Montgomery

Trial Library Platform Expands Clinical Trial Access for Patients - Hala Borno

RaLu Trial: Sequence of Radium Then Lutetium in mCRPC Management - Kambiz Rahbar

Response and Progression Criteria for PSMA PET: Imaging Prostate Cancer Outcomes - Wolfgang Fendler

Pelvic Muscle Rehabilitation after Radical Prostatectomy - Diane Newman

Single-Cell Analysis Reveals Heterogeneity in Treatment-Resistant Prostate Cancer - Samir Zaidi

Early Palliative Care Boosts Quality of Life for Prostate Cancer Patients - Michael Rabow

ctDNA Assay Detects AR Enhancer Alterations Linked to Poor Survival - Russell Pachynski, Aadel Chaudhuri & Christopher Maher

Which Patients with High-Risk First BCR After Radical Prostatectomy are Candidates for Systemic Therapy Alone Without Local Salvage RT? "Presentation" - Bertrand Tombal

In Patients Who Receive Salvage Radiation Therapy For BCR, Who Needs Additional Systemic Therapy, What and For How Long?" Presentation" - Daniel Spratt

Timing of Salvage Radiotherapy in Recurrent Prostate Cancer Management "Discussion"

In Patients with BCR and Positive Lesion(s) in the Pelvis – Stereotactic or Whole Pelvis RT? "Presentation" - Paul Nguyen

Introduction to mHSPC: Key Prognostic and Predictive Factors "Presentation" - Matthew Smith

Low-Volume mHSPC: When to Intensify Treatment "Presentation" - Robert Jones

In Which Patients with Synchronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Oliver Sartor

Which Patients with mHSPC Should Get Triplet Systemic Therapy: ADT plus Docetaxel plus ARPI? "Presentation" - Nicholas James

Should the Primary be Treated in Synchronous High-Volume mHSPC? "Presentation" - Sandy Srinivas

In Which Patients with Metachronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Thomas Zilli

Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice? "Presentation" - Michael Morris

Optimal Treatment Sequencing in Metastatic Prostate Cancer "Discussion"

Update on the IRONMAN Project "Presentation" - Alicia Morgans

Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break? "Presentation" - Bertrand Tombal

Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better? "Presentation" - Mary-Ellen Taplin

How to Manage Patients with Low-Volume on Conventional and High-Volume on NGI "Presentation" - Dana Rathkopf

Management of Patients with mHSPC and Early Progression on Combination Therapy "Presentation" - Christopher Sweeney

Management of Frail Patients with mHSPC "Presentation" - Maria De Santis

Future Changes in the Setting of mHSPC "Presentation" - Gerhardt Attard

Patient Preferences in Prostate Cancer De-Escalation Strategies "Discussion"

Cardiovascular Complications in Advanced Prostate Cancer – How to Prevent Them and How to Monitor Patients? "Presentation" - Thomas Suter

How to Select ADT and ARPI Based on CV Risk Profile "Presentation" - Charles Ryan

Importance of Bone Protection in Prostate Cancer Treatment "Presentation" - Noel Clarke

Gynecomastia – How to Assess and Treat? "Presentation" - Lisa Horvath

Hot Flushes – How Can We Help Our Patients? "Presentation" - Anthony Joshua

Testosterone Recovery After Stopping ADT – Who Is at Risk for Long-Term Non-Recovery? "Presentation" - Pierre Blanchard

Balancing Risks and Benefits of ADT in Prostate Cancer Treatment "Discussion"

Tailoring PARP Inhibitor Therapy for mCRPC Based on Genetic Alterations "Discussion"

When to Do Tumour Genomic Profiling in Advanced Prostate Cancer and What? "Presentation" - Niven Mehra

Ideal Sequence After ADT Alone or ADT plus ARPI for mHSPC "Presentation" - Ian Davis

Ideal Sequence After ADT plus ARPI plus Docetaxel for mHSPC "Presentation" - Karim Fizazi

Best Use of PARP Inhibitors in mCRPC "Presentation" - Joaquin Mateo

PARP Inhibition Dissected – in Which DNA Repair Gene Alterations Works Which PARP Inhibitor? "Presentation" - Johann De Bono

How to Manage Side Effects of PARPi? "Presentation" - Elena Castro

Managing PSA Recurrence After Prostate Cancer Surgery Treatment "Discussion"

PARP Inhibitors in Prostate Cancer Challenges and Opportunities in Clinical Practice "Discussion"

Lancet Commission on Prostate Cancer– the Forthcoming Surge in Prostate Cancer Raises Very Different Issues to the Ones We Face Today "Presentation" - Nicholas James

How Do We Modify the Diagnostic Pathway to Deal with Rising Rates of Prostate Cancer in Africa? "Presentation" - Onyeanunam Ngozi Ekeke

Dealing with Inequality - the Promise and Pitfalls for Social Media and AI for Prostate Cancer in Disadvantaged Populations "Presentation" - Stacy Loeb

How to Deal with the Projected Rise of Prostate Cancer Cases in the Chinese Healthcare System "Presentation" - Dingwei Ye

Global Cancer Care Challenges & Solutions in Developing Nations "Discussion"

Notch Signaling Suppresses Neuroendocrine Differentiation in Advanced Prostate Cancer - Sheng-Yu Ku

Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment - Louise Emmett

Elevated CBP/p300 Expression Linked to Poor Outcomes in Advanced Prostate Cancer - Ayesha Shafi

Comprehensive Atlas Details Prostate Cancer Chromatin Patterns - Raunak Shrestha

MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer - Phuoc Tran & Tim Showalter

Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl

Olaparib Effective in BRCA2-Altered Biochemical Recurrence Post-Prostatectomy in Phase 2 Study - Catherine Handy Marshall

Epigenetic Profiling Identifies Biomarkers Predicting Resistance to AR-Targeted Therapy in mCRPC - Wilbert Zwart

ARROW Study Reveals Iodine-131 PSMA Efficacy in Advanced Cancer - Evan Yu

Metformin Study Reveals Weight Management Benefits for ADT Therapy - Silke Gillessen

Humanized Mice Reveal Role of Immune System in Prostate Cancer Therapy Efficacy - Steven Kregel

UpFrontPSMA Trial Results: Lutetium-177 PSMA-617 in Hormone-Sensitive Prostate Cancer, Journal Club - Phillip Koo & Zachary Klaassen

STAMPEDE2 Trial Explores Combination Niraparib and Abiraterone in mHSPC - Sarah Howlett & Mahaz Kayani

AR Pathway Inhibitors vs Taxanes in mCRPC ProBio Trial - Bram De Laere

ARANOTE Trial Implications for Metastatic Prostate Cancer Management, Journal Club - Rashid Sayyid & Zachary Klaassen

First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract

Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad

INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra

STEAP1-Targeted T-Cell Engager Demonstrates Efficacy in mCRPC Patients - William Kevin Kelly

Emerging DLL3-Targeted Therapies Demonstrate Efficacy in Neuroendocrine Prostate Cancer - Himisha Beltran

Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck

Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann

Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard

First-in-Class AR Degrader Shows Promise in Castration-Resistant Prostate Cancer - Dana Rathkopf

TALAPRO-2 Analysis: Talazoparib Enzalutamide Combo in Pretreated mCRPC - Neeraj Agarwal

CONTACT-02 Trial Results: Cabozantinib Plus Atezolizumab for mCRPC - Neeraj Agarwal

PEACE-3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad

Accelerated 177Lu-PSMA-617 Protocol Tested in STAMPEDE2 - Minal Padden-Modi & Nicholas James

RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca

Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad

Utilizing the Decipher® mRNA Score for Risk Stratification in mHSPC - David Morris and Ashley Ross

PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC - Bertrand Tombal

STAMPEDE2 SABR Trial for Oligometastatic Prostate Cancer Treatment - Hoda Abdel-Aty

UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad

T-Cell Engagers in Prostate Cancer Treatment - Neeraj Agarwal

Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros

EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore

ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo

PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel

PRINCE Trial Highlights Early Detection of Prostate Cancer Progression with PSMA PET-CT - Michael Hofman

SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment - Oliver Sartor

2024 NCCN Prostate Cancer Guidelines: Updates in M1 CSPC Treatment - Rashid Sayyid & Zachary Klaassen

Advanced Prostate Cancer: Understanding Out-of-Pocket Medication Costs - Daniel Joyce

STORM Trial Examines Elective Nodal Radiotherapy in Treating Prostate Cancer Recurrence - Piet Ost

Cardiovascular Risks of ARSIs in Prostate Cancer: Meta-Analysis Findings, Journal Club - Rashid Sayyid & Zachary Klaassen

RADIOSA Trial: SBRT vs SBRT+ADT for Oligorecurrent Prostate Cancer - Giulia Marvaso

Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy - John Babich

Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer - Daniel Petrylak

Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan

PSMA PET in Prostate Cancer: Balancing Sensitivity and Clinical Relevance - Ravi Madan

PSMA-PET/CT Guided Salvage Radiotherapy: Improving Prostate Cancer Outcomes - Constantinos Zamboglou

Copper-67 (Cu-67 or 67Cu) in Cancer Therapy: Current Developments and Future Potential - Alan Taylor

Advancing Radiopharmaceuticals: From Lead-212 to Pre-Targeting Strategies - Michael Schultz

Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff

Lead-212 Radiopharmaceuticals: Next Frontier in Cancer Treatment - Emanuele Ostuni

Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo

2024 NCCN Guidelines: Managing Bone Health in Prostate Cancer Patients - Rashid Sayyid & Zachary Klaassen

2024 NCCN Guidelines: Preventing Skeletal Events in Prostate Cancer - Rashid Sayyid & Zachary Klaassen

Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner

PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi

Post-Prostatectomy Care: Variability in Treatment for Lymph Node Positive Prostate Cancer - Daniel Triner

Meta-Analysis Evaluates Cardiovascular Risks of AR Inhibitors in Prostate Cancer - Omar El-Taji & Ashwin Sachdeva

PROSTATE-IQ Trial: Reducing ADT Burden in Salvage Radiotherapy - Karen Hoffman

VA's Million Veterans Program Reveals Crucial Genetic Data for Prostate Cancer Treatment - Bruce Montgomery

SECuRE Trial: Copper-67 SAR-bisPSMA Therapy for Prostate Cancer - Geoffrey Johnson

Genomic Alterations and Lutetium PSMA Response in Prostate Cancer - Alexandra Sokolova

CYCLONE 2 Trial Results: Abemaciclib in Metastatic Castration-Resistant Prostate Cancer - Matthew Smith

Prostate Cancer Diversity Revealed: AR and Neuroendocrine Signatures - Yu-Wei Chen

PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results - Tanya Dorff

Mental Health and Prostate Cancer in the Veterans Population - Zachary Klaassen

IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb

Targeting EZH2 in Prostate Cancer: The Role of Mevrometostat in Preventing Neuroendocrine Differentiation - Michael Schweizer

Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh

Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal

Enzalutamide Plus 5-Alpha Reductase Inhibitors for Castrate-Sensitive Prostate Cancer: A Phase 2 Trial - Deepak Kilari

Dose-Escalation of Lutetium PSMA: Final Results from a Phase I/II Trial - Scott Tagawa

Exploring Genetic Counseling in Veterans with Advanced Prostate Cancer - Daniel Kwon

Advancing Treatment for High-Risk Biochemical Recurrence Prostate Cancer: The ARASTEP Trial - Alexander Chehrazi-Raffle

OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan

ARV-766: Efficacy and Safety of a Second-Generation AR Degrader in Prostate Cancer - Daniel Petrylak

CHAARTED 2 Study Shows PFS Benefit with Cabazitaxel in Metastatic Prostate Cancer in Phase 2 - Christos Kyriakopoulos

Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi

PROMISE Criteria: Enhanced Survival Prediction in Prostate Cancer with PSMA PET - Wolfgang Fendler

hK2-Targeted Radioligand Shows Promise in Treating Advanced Prostate Cancer: Phase I Findings - Michael Morris

Predicting Response to Bipolar Androgen Therapy: A Blood-Based Biomarker Approach - Samuel Denmeade

COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection - Phillip Koo

Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Fred Saad

UCHL1: A Potential Biomarker and Therapeutic Target for Neuroendocrine Prostate Cancer - Tanya Stoyanova

Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman

Behavioral Interventions for Mitigating ADT Side Effects in Prostate Cancer - Brian Gonzalez

Hypofractionation in Prostate Cancer Radiotherapy: Balancing Efficacy and Safety - Neha Vapiwala

Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin

Radiating the Primary Tumor in Metastatic Hormone-Sensitive Prostate Cancer - Sandy Srinivas

EMBARK Trial: Enzalutamide Monotherapy and Combination Therapy for High-Risk Biochemical Recurrence - Neal Shore

Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence - Daniel Spratt

COBRA Trial Shows Promise for 64Cu-SAR-bisPSMA PET in Biochemical Recurrence - Neal Shore

Prognostic and Predictive Factors in Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith

Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett

Sequencing Therapies in mCRPC After Progression on Combination Treatment - Ian Davis

Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis

Redefining Low-Volume Metastatic Prostate Cancer in the Era of PSMA PET Imaging - Oliver Sartor

Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer - Michael Morris

The EvoPAR-Prostate 01 Trial: Novel PARP Inhibitor Saruparib in mHSPC - Neeraj Agarwal

The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo

Reprogramming Tumor-Associated Macrophages with Glutamine Antagonist JHU083 in Prostate Cancer - Jelani Zarif

Non-Invasive Detection of Neuroendocrine Prostate Cancer Through Targeted Cell-Free DNA Methylation - Himisha Beltran & Francesca Demichelis

Bone Health in Advanced Prostate Cancer: Findings from the STAMPEDE Trial and Hospital Episode Statistics - Noel Clarke

Evidence-Based Guidelines Update Salvage Radiation Protocols - Todd Morgan

PEACE V (STORM) Trial: Comparing MDT vs. Elective Nodal Irradiation for Oligorecurrent Prostate Cancer - Thomas Zilli

Darolutamide Outcomes in European Patients with Metastatic Hormone-Sensitive Prostate Cancer from the ARASENS Trial - Bertrand Tombal

The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore

A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy - Beyond the Abstract

A US Real-World Study of Treatment Patterns and Outcomes in Localized or Locally Advanced Prostate Cancer Patients - Beyond the Abstract

Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses

Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi

PARP Inhibitor + AR Signaling Inhibitor Combos Improve mCRPC Outcomes in Meta-Analysis - Rashid Sayyid

Examining the 340B Program's Role in Mitigating Disparities in Prostate Cancer Treatment - Kassem Faraj

Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce

Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans

Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore

Advancing Personalized Medicine: Examining Trop2 as a Biomarker to Stratify Prostate Cancer Patient Risk - Tanya Stoyanova

Biochemical Recurrence in Patients with Prostate Cancer after Primary Definitive Therapy: Next-Generation Imaging and Treatment Based on Risk Stratification - Beyond the Abstract

COMBAT Trial Yields Promising Results for Bipolar Androgen Therapy Plus Nivolumab in Metastatic Castration-Resistant Prostate Cancer - Mark Markowski & Emmanuel Antonarakis

PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy - Boris Hadaschik

CONTACT-02 Phase III Trial Findings on Cabozantinib-Atezolizumab Combination in mCRPC - Neeraj Agarwal

Patient Selection for PSMA Radioligand Therapy - Ephraim Parent

BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George

Comprehensive Multi-Region Sampling Reveals Extensive Genomic Heterogeneity in Metastatic Prostate Cancer - Alexander Wyatt

Distinct Mesenchymal Cell States Mediate Prostate Cancer Progression - Massimo Loda

ProBio Trial Demonstrates Improved Outcomes Using Biomarker-Guided Therapy Selection for Metastatic Prostate Cancer - Henrik Grönberg

A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer - Beyond the Abstract

Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen

Apalutamide plus Androgen Deprivation Therapy in Clinical Subgroups of Patients with Metastatic Castration-Sensitive Prostate Cancer: A Subgroup Analysis of the Randomised Clinical TITAN Study - Beyond the Abstract

Novel Biomarker Analysis Reveals SPOP Gene Mutation Unlocks Sensitivity to PARP Inhibitor Treatment in Metastatic Castration-Resistant Prostate Cancer - Emmanuel Antonarakis & Jacob Orme

Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic

ENZA-p Trial Explores Enzalutamide-Lutetium Combination in Prostate Cancer - Louise Emmett

Harnessing Tumor Biology to Improve Outcomes in Advanced Hormone-Sensitive Prostate Cancer - Gerhardt Attard

STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly

Shifting Clinical Trial Design Towards Improving Patient Enrollment - Michael Morris

AMG 509's Potential in Prostate Cancer Therapy - Michael Morris

Genetic Testing Reveals Treatment Opportunity and Disparity in Advanced Prostate Cancer - Colin Pritchard

Medicare Data Compares Enzalutamide and Abiraterone Outcomes in mCRPC Patients - Dan George

Sequencing Therapies in Advanced Prostate Cancer Requires Balancing Many Factors - Rana McKay

The PSMAfore Trial and its Role in Shaping Future Prostate Cancer Treatments - Oliver Sartor

AKT Inhibitors – Targeting PI3K/AKT/MTOR Signaling Axis - Cora Sternberg

Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming

Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer - Rana McKay

Bone Health Management for Advanced Prostate Cancer - Fred Saad

Tumor Heterogeneity Selective Pressure – Why We Need New Targets? - Oliver Sartor

Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi

PARP Inhibitors: Targeting DNA Repair Pathways - Neal Shore

The Biological Basis of Metastatic Prostate Cancer – The Unmet Medical Need for New Targets and Novel Treatment Pathways - Dan George

The Critical Intersection of Androgen Receptor Pathways and Cell Cycle Regulation in Prostate Cancer Therapy - Rana McKay

The Current Treatment Landscape in Metastatic Hormone-Sensitive Prostate Cancer - Andrew Armstrong

PSMA PET as a Biomarker for Advanced Prostate Cancer - Oliver Sartor

Treatment Decision Making in mCRPC: The Urologist and Patient “What the Patient Needs to Know” About His Disease and Treatment Options? - Brenda Martone

Multidisciplinary Approach in the Treatment of Metastatic Prostate Cancer - Robert Dreicer

Clinical Implications and Patient Care: The SNMMI Consensus on Lutetium PSMA 617 Therapy for Advanced Prostate Cancer - Heather Jacene & Oliver Sartor

Influencing Best Practices for Genomic and Germline Testing in Urology - Abhishek Srivastava

Comprehensive Genomic Profiling and Treatment Patterns Across Ancestries in Advanced Prostate Cancer - Brandon Mahal

The REASSURE Trial: Long-Term Safety of Radium-223 in Advanced Prostate Cancer - Oliver Sartor

The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer - David Quigley

The ECLIPSE Trial: Investigating Lutetium-177 in the Pre-Chemotherapy Space in Advanced Prostate Cancer - Daniel Saltzstein

DDR and PARP Inhibition: What's the Damage? - David VanderWeele

Prospective Monitoring of Biochemical Recurrence with PSMA PET - Ravi Madan

Understanding the Potential and Challenges of Sipuleucel-T and Radium-223 in the Management of Metastatic Castration-Resistant Prostate Cancer - Sumit Subudhi

PSMA-PET Implications for Extent and Survival Outcomes in High-Risk nmCRPC: An International Study - Boris Hadaschik

Analyzing Quality of Life and Survival from CHAARTED Prostate Cancer Trial - Daniel Sentana Lledo

Primary Analysis of STARTAR: A Phase 2 Salvage Trial for High-Risk Prostate Cancer with Biochemical Recurrence - Tian Zhang

The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mCRPC - Susan Halabi

A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in mHSPC: A-DREAM - Atish D. Choudhury

Early Aggressive Treatment Shows Promise for Prostate Cancer Recurrence - Stephen J. Freedland

Understanding BRCA Mutations: The Pivotal Impact of the CAPTURE Study - David Olmos

The Added Value of Docetaxel in Combination with ADT and ARPI for the Treatment of mHSPC - Ursula Vogl

Navigating Salvage Radiotherapy with Insights from PSMA PET - Jeremie Calais

Predictive Modeling for 177Lu-PSMA-617 Therapy in Patients with mCRPC - Ken Herrmann

Unlocking Prostate Cancer Treatment: The Pathway of CAR T Targeting Prostate Stem Cell Antigen - Tanya Dorff

Integration of Lutetium into Clinical Practice: A Urologist's Perspective - Neal Shore

Beyond BRCA-1 and 2: The Impact of the TALAPRO-2 Study on Prostate Cancer Care - Cora Sternberg

Navigating the Future of Prostate Cancer Treatment and Global Access at APCCC 2024 - Silke Gillessen

Beyond Medical Advancements: Addressing Financial and Personal Challenges in Metastatic Castration-Sensitive Prostate Cancer Treatment - Neeraj Agarwal

Combating Prostate Cancer: The Role of the NRG-GU-011 Study in Transforming Treatments - Bridget Koontz

TALAPRO-2 Study Reveals Efficacy and Tolerability of Talazoparib Combination for Prostate Cancer - Neeraj Agarwal

Exploring Darolutamide's Impact on Time to Pain Progression Based on Disease Volume in the ARASENS Study - Matthew Smith

Prostate Cancer Treatment Revolution: Radiotherapy and Abiraterone in the Spotlight of PEACE-1 - Alberto Bossi

Decoding Exceptional Responses: The National Cancer Institute's Unique Prostate Cancer Study - Fatima Karzai & Rana McKay

Unlocking Prostate Cancer Therapeutics: The Potential of Minor Spliceosome Inhibition - Mark Rubin

Investigating the Role and Therapeutic Potential of B7-H3 in Prostate Cancer - Christina Guo

Immune Checkpoint B7-H3 is a Therapeutic Vulnerability in Prostate Cancer Harboring PTEN and TP53 Deficiencies - Di Zhao

Combination Treatment in Metastatic Prostate Cancer: Is the Bar Too High or Have We Fallen Short? - Kenneth Chen

PSMA Expression in Advanced Prostate Cancer: Implications for Targeted Therapies -Himisha Beltran

Insights into Global Treatment Patterns for Advanced Prostate Cancer: The IRONMAN Registry - Lorelei Mucci &. Dan George

Exploring PSMA Expression Variations in Metastatic Prostate Cancer: The Role of Reversible Epigenetic Changes - Michael Haffner

EMBARK Trial Shows Promising Results for High-Risk Prostate Cancer Treatment, Enzalutamide's Impact on Metastasis-Free Survival - Neal Shore

Improving Genetic Testing Rates in Advanced Prostate Cancer - Pedro Barata

DLL3 Targeting Bispecifics: A New Hope for Tough-to-Treat Prostate Cancer Patients - Rahul Aggarwal

Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad

Treating Biochemical Recurrence With Enhanced Therapy Added to Standard of Care and Targeted Radiation Using PET Imaging, ECOG-ACRIN EA8191 (INDICATE) - Neha Vapiwala

NCCN Guidelines: A Framework for PET Imaging Integration in Prostate Cancer Care - Edward Schaeffer

SPARE Trial's Implications for Prostate Cancer Patients - Carsten-Henning Ohlmann

Unveiling the Clinical Potential of ctDNA: Implications for Prostate Cancer Management - Neeraj Agarwal

Immune System Biology of Androgen and AR Functions in T cells in Prostate Cancer - Amy Moran

Advances in Liquid Biopsies for Guiding Cancer Therapy - Jeffrey Ross

Engineered Cell Therapies for Metastatic Castrate-Resistant Prostate Cancer - Saul Priceman

The Effect of Metastasis-Directed Therapy (MDT) on Oligometastatic Castration-Sensitive Prostate Cancer Outcomes - Philip Sutera

Geographic Variation in the Use of Doublet Therapy for Metastatic Prostate Cancer - Samuel Washington

Exploring the Molecular Mechanisms of Tumor Progression in Metastatic Prostate Cancer among Men of African Ancestry (MET-PAAM) - Clayton Yates

Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis

Using Liquid Biopsies in Clinical Practice to Inform Decision Making for Prostate Cancer Care - Joshua Lang

Contact-02: A Phase III Trial Shaping the Future of Metastatic Prostate Cancer Care - Neeraj Agarwal

Exploring the Landscape of mCRPC: PARP Inhibitors, PSMA Radioligand Therapy, and More - Alicia Morgans

The AFT-19 Study: A Comprehensive Look at High-Risk Prostate Cancer Treatment - Rahul Aggarwal

The Promising Path of PSMA PET Imaging and Lutetium-177-PSMA in GU Oncology and Prostate Cancer Treatment - Susan Slovin

Exploring the SPLASH Trial: PSMA I&T Lutetium-177 in Pre-Chemo Metastatic CRPC - Oliver Sartor

Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard

CAR T and Cellular-Based Therapies - Vivek Narayan

Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans

Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clara Hwang

The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff

Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans

Extending Prostate Genetic Awareness, Navigation and Delivery for Genetic Testing in Males of African American Decent - The EXPAND Network, 2021 PCF-Pfizer Global Health Equity Challenge Award - Veda Giri

Immune Checkpoint B7-H3 - APCCC 2022 - Emmanuel Antonarakis

Timing and Intensity of ADT in Biochemical Recurrence - Channing J. Paller

When and How Much: A Deep Dive into the RADICALS Trial's Questions on Radiotherapy and Hormone Therapy - Nicholas James

An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt Attard

From ADT to Triplet Therapy: Rethinking Treatment Paradigms in Metastatic Hormone Sensitive Prostate Cancer - Matthew Smith & Kim Chi

What Is the Evidence of Systemic Therapies (Alone or in Combination With MDT) in Oligometastatic mHSPC? APCCC 2022 Presentation - Mary Ellen Taplin

Impact of Histology Variants (Ductal/Intraductal/Cribriform) on Treatment Recommendation Presentation - Declan Murphy

Efficacy and Safety of 177Lu-PNT2002 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer in the SPLASH - Neil Fleshner

Update on Immune Checkpoint Inhibitors APCCC 2022 Presentation - Emmanuel Antonarakis

Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment APCCC 2022 Presentation - Eric Small

Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of Muscle Strength? APCCC 2022 Presentation - Heather Cheng

Smarter Screening In Prostate Cancer - Sigrid Carlsson

Emerging Therapies and Therapeutic Targets in Prostate Cancer - Mark Rubin

Immunotherapy and PARP Inhibitors in Biochemical Recurrent Prostate Cancer - Alexandra Sokolova

How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi

The 6th Global Summit On Precision Diagnosis and Treatment Of Prostate Cancer - Faina Shtern, The AdMe Tech Foundation

The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy - Stephen Freedland

The Efficacy and Safety of Relugolix versus Leuprolide in the HERO Study in Men with Advanced Prostate Cancer Based on Baseline BMI - Fred Saad

Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo

Patient-Centric Approaches: The Urgent Need for Genetic Testing in Prostate Cancer - Brittany Szymaniak

Advancing Genetic Testing in Metastatic Prostate Cancer - Brenda Martone

Identifying the Right Patients for Treatment with Radium-223 for mCRPC - Brenda Martone

PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad

Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans

The Management of High-Risk Localized Disease and Double Therapy in the mCRPC Setting - Andrey Soares

Lessons Learned in the STAMPEDE Trial - Nicholas James

Real-World Differences in Outcomes with First-Line Abiraterone Therapy Between African American and White Men with mCRPC - A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher

Clinical Trials in Progress: PSMA-Based Radioligand, 177Lu-PNT2002 For Men With Metastatic Castration-Resistant Prostate Cancer - The SPLASH Study - Neil Fleshner

Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne

The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen

The Risk of Prostate Cancer in Men with Inherited Germline TP53 Variants - Kara Maxwell

First Results of MAGNITUDE – Niraparib with Abiraterone Acetate and Prednisone a First-Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Kim Chi

From the Stage to the Clinic and Back: Medicine and Burnout - Stuart H. Bloom

Risk Stratification in Metastatic Prostate Cancer: The Genomic Approach - Leanne Schimke

Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio

A Trial of VERU-100 for the Treatment of Advanced Prostate Cancer – Ronald Tutrone

COSMIC-021 Study: A Breakthrough in Metastatic CRPC Treatment with Cabozantinib and Atezolizumab - Neeraj Agarwal

Impact of Age on Castration Rates from The HERO Study – Michael Cookson

HERO Trial: Oral Relugolix for ADT in Advanced Prostate Cancer - Thomas Keane

Genomic Analysis and Assessment of Treatment Patterns To Better Understand Disparities in Advanced Prostate Cancer – Brandon Mahal

Ensuring Patients Have Access to Radium-223 as a Therapeutic Option: The DORA Trial - Michael Morris

Treatment Sequencing in Castrate-Resistant Metastatic Cancer - Mark Fleming

Relugolix in the Treatment of Advanced Prostate Cancer- Neeraj Agarwal

Transitioning Patients to an Oral GnRH Antagonist and Optimizing Patient Outcomes - Brenda Martone

Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross

Should Checkpoint Inhibitors Ever Be Used Outside of a Clinical Trial in Prostate Cancer - James Gulley

Stereotactic Ablative Body Radiotherapy in Patients in Oligometastatic Cancers: A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

First and Only Oral GnRH Receptor Antagonist Orgovyx for the Treatment of Advanced Prostate Cancer - Charles Ryan & Alicia Morgans

Precision Oncology Program for Cancer of the Prostate (POPCaP) - Matthew Rettig

Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer - Karim Fizazi

PROSPER Trial: Significant Improvement in Metastasis-Free Survival (MFS) and Overall Survival (OS) Demonstrated Nonmetastatic Castration-Resistant Prostate Cancer Patients - Fred Saad

HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore

Low Carbohydrate Diets in Men with Recurrent Prostate Cancer: The CAPS2 Study - Stephen Freedland

The Statisticians Perspective on Methods of Comparing Prostate Cancer Clinical Trial Data - Matthew Sydes

AR Indifferent Subtype Tumors in Prostate Cancer - Ana Aparicio

Supportive Therapy in Androgen Deprivation (STAND) - Rahul Aggarwal

An Update on the PRONOUNCE Trial, Comparing the Occurrence of Major Adverse Cardiovascular Events in Patients with Prostate Cancer and Cardiovascular Disease - Susan Slovin

Testosterone Replacement in the Treatment of Advanced Prostate Cancer - Sam Denmeade and Michael Schweizer

Advanced Prostate Cancer Clinic: What’s Changing? - Maha Hussain

Understanding Differences in Outcomes of Men with Prostate Cancer Based on Race and Ethnicity - Christopher Logothetis

Management of Advanced Prostate Cancer in the Middle East - Deborah Mukherji

Aggressive Variant Prostate Cancer: Identifying Patients with Specific Molecular Signature - Ana Aparicio

Interpreting Phase III Clinical Trial Data - Susan Halabi

The Changing Landscape for Locally Advanced Prostate Cancer- Maria de Santis

Disparities and Outcomes in Men with Prostate Cancer - Susan Halabi, Mindy Hebert-DeRouen, and Daniel George

The IRONMAN - An International Registry for Men with Advanced Prostate Cancer - Dana Rathkopf

Advancing Prostate Cancer Research - The Prostate Cancer Clinical Trials Consortium (PCCTC) - Sarah Wise

How to Treat Men With Newly Diagnosed cN1 cM0 Prostate Cancer - Systemic Therapy Options - Nicholas James

Definitions and Concepts of Oligometastatic Prostate Cancer - Interview with Robert Reiter

Managing the Complications of Androgen Deprivation Therapy - Mark Frydenberg

Imaging Modalities to Treat Node-Positive Disease - Interview with Declan Murphy

How to Treat Men with pN1 Prostate Cancer - Presentation - Alberto Bossi

Disadvantages of PSMA PET/CT in Advanced Prostate Cancer Imaging Presentation - Ian Davis

Radiation Therapy Options for Men with Clinically Node-Positive Prostate Cancer - Mack Roach

The Future of Biomarkers in Advanced Prostate Cancer - Mark Rubin

Radiation Therapy Options for Men with Newly Diagnosed cN1 cM0 Prostate Cancer - Mack Roach

How Best to Treat cN1 Prostate Cancer - Karim Fizazi

Ethnicity and Prognosis of Prostate Cancer - Christopher Logothetis

Testosterone Measurement – Which Test and When? - Martin Gleave

The Aging Population: Oncogeriatric Assessment and Treatment Considerations Presentation - Joe O'Sullivan

The Management of Hot Flushes in Advanced Prostate Cancer - Mark Frydenberg

The Management of Sexuality and Incontinence in Advanced Prostate Cancer Presentation - Inge Van Oort

A Subgroup Analysis of mCRPC Clinical Trials Presentation - Susan Halabi

The Future of Advanced Prostate Cancer Management: In Locally Advanced Prostate Cancer Presentation - Alberto Briganti

The Best Use of Antiresorptive Therapy in CRPC Presentation - Matthew Smith

The Management of Fatigue, Cognition, and Dementia in Prostate Cancer Patients Presentation - Charles Ryan

Management of ADT Metabolic Complications: Assessment, Monitoring, Interventions Presentation - Neal Shore

The Future of Advanced Prostate Cancer Management: Access to Treatments Presentation - Karim Fizazi

The Future of Advanced Prostate Management Presentation - Mark Rubin

The Future of APC Management in Polymetastatic Disease Presentation - William Oh

The Neuroendocrine Prostate Cancer Spectrum Diagnosis and Treatment Presentation - Eleni Efstathiou

Which Systemic Therapy for Which Patient with Newly Diagnosed Metastatic Prostate Cancer Presentation - Chris Sweeney

Recurrent Disease After Radiation Therapy, the Role of the Radiation Oncologist - Felix Feng and Piet Ost

Sinai Researchers Find First Mechanistic Link between World Trade Center Dust & Prostate Cancer - William Oh

Looking Into the Future: Oligometastatic Disease Presentation - Misha Beltran

Movember Session: Outcomes Research – IRONMAN Project - Alicia Morgans and Ian Davis

How to Treat Men with Newly Diagnosed cN1 cM0 Prostate Cancer: Surgery Options Presentation - Declan Murphy

Management of Men With PSA Recurrence or Persistence After Prostatectomy: Presentation - Christopher Evans

Management of Men with PSA Recurrence After Radical Local Radiation Therapy Presentation - Felix Feng

Disparities in Prostate Cancer Management in the United States Presentation - Alicia Morgans

Pharmaco-ethnicity and Its Impact on Treatment Presentation - Darren MC Poon

APCCC 2019 Global vs. Expert Consensus in the Management of Advanced Prostate Cancer Study - Charles Ryan

Clinical Utility of Molecular Biomarkers Presentation - Johann de Bono

Baseline PSA Level in Midlife and Aggressive Prostate Cancer in African American Men - Mark Preston

Optimizing Care in Localized Prostate Cancer - Mary-Ellen Taplin and Adam Kibel

Credentialing Imaging as an Outcome Measure in Prostate Cancer - Lawrence H. Schwartz and Michael J. Morris

Latin American Oncology Group (LACOG), a Cooperative Group Consensus - Fernando Maluf

Radiation Therapy Options for Prostate Cancer - Paul Nguyen

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial - Fred Saad

Cognitive Function in Men with Prostate Cancer - Claire Pernar

Ben Maughan Highlights Key Practice Changing Prostate Cancer Data

Real-World Evaluation of Disparities in Prostate Cancer Outcomes - Daniel Spratt

Biomarkers Across the Spectrum of Prostate Cancer- Anis Hamid and Chris Sweeney

Integrating Genomics into Localized Prostate Cancer - Todd Morgan and Daniel Spratt

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines - Oliver Sartor

Precision Oncology: The PCF - Veterans Affairs (VA) Initiative - Bruce Montgomery

Urologists Perspectives on Prostate Cancer Presentations from ASCO GU 2019 - Edward Schaeffer

Challenges in the Treatment of Localized Prostate Cancer - Srikala Sridhar

Practice Patterns of Active Surveillance in Prostate Cancer - Matt Cooperberg

Results from Recent Pivotal Trials in Prostate Cancer - Cora Sternberg

Prostate Cancer Disparities in the VA Health System - Megan McNamara

A Look at Established Paradigms in Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer - Tom Keane

Optimizing ADT in Prostate Cancer Patients - Tom Keane

3D Prostate Gland Uptake of 18F Choline PET CT - Association with Overall Survival in Patients with Hormone-naive Prostate Cancer - May Sadik

Neoadjuvant Therapy Prior to Prostatectomy - Mary-Ellen Taplin

Life-Prolonging Treatments for Advanced Prostate Cancer - Maha Hussain

Disparities in Prostate Cancer Clinical Trial Participation - Hala Borno

18F Fluorocholine PET-Whole Body MR in the Staging of High Risk Prostate Cancer - Ur Metser

68Ga PSMA 11 PET MRI in Intermediate and High Risk Prostate Cancer - Claudia Zacharias

A Review of Imaging Modalities in Prostate Cancer - Peter Pinto

Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus ADT for Men with Advanced Prostate Cancer - Tom Keane

A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney

Targeting Treatment to Subtypes in Prostate Cancer - Misha Beltran

Quality of Life and Health Economics Data: STAMPEDE Trial - Nick James

ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle Burgess

Genetic Screening for Patients with Prostate Cancer - Todd Morgan

IRONMAN Registry: A Global Landmark Trial in Advanced Prostate Cancer

Current State of Liquid Biopsies in Prostate Cancer - Gert Attard

Nuclear Medicine and Lutetium 177 PSMA Therapies - Carmel Pezaro

The United States Preventive Services Task Force PSA Screening Recommendations- David Penson

Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi

Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng

Optimizing Care in Patients with High Risk Prostate Cancer - Interview with Edward Schaeffer

Use of Conservative Management for Low-Risk Prostate Cancer - Interview with Stacy Loeb

Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov

Clinical Implications of the Abi Race Study: Interview with Dan George

The RADICAL PC Project - Jehonathan Pinthus

New Concepts in ADT- Thomas Keane

Quality of Life During Treatment with Chemohormonal Therapy - Alicia Morgans

Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin

Advanced Prostate Cancer Videos

Login